News | December 05, 2011

Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Demonstrates Promise

Stem Cells might be used to restore heart function by replacing the dead heart muscle following myocardial infacrtions.

December 5, 2011 – University Hospitals Case Medical Center researchers could still be close to giving heart attack patients a second chance…just not as they originally thought.

The "LateTIME" trial was a study of adult stem cells (autologous) harnessed from bone marrow that were believed to have the ability to improve heart function after an attack if injected into the heart within two weeks of the attack.

Results were released this week at the 2011 American Heart Association (AHA) Scientific Sessions conference and were subsequently published this week in Journal of the American Medical Association (JAMA). The results have shown the injections within that timeframe were not favorable, but the concept showed great promise, according to an accompanying JAMA editorial that assessed the trial.

Despite the initial low return, the therapy had effectiveness for some of the patients that were enrolled in the trial as demonstrated by improved heart function post stem cell injection.

Both UH Case Medical Center's Drs. Dan Simon and Marco Costa, co-investigators in the LateTIME study, are currently participating in a similar trial, "TIME," which already has reduced the time between attack and stem cell injection.

The pair is optimistic the time variable adjustment in the new trial will lend favorable outcomes.

"We have reason to believe, as supported by data, that an adjusted injection timeframe could yield stronger results and support for stem cell injections rebuilding damaged heart muscle and function," said Simon, chief of cardiovascular medicine at UH Case Medical Center and the Herman K. Hellerstein Professor of Cardiovascular Research, Case Western Reserve University School of Medicine.

"The results were not positive, but if you put it into perspective, the foundation or blueprint for success was discovered and that could certainly lead to advanced treatment options for these patients," said Costa, director of the Interventional Cardiovascular Center and Research & Innovation Center at UH Case Medical Center as well as a professor of medicine at Case Western Reserve University School of Medicine.

The shared theories in both trials is that the specialized cells could have the ability to promote blood vessel growth, prevent cell death and transform themselves into a number of tissues, including muscle. After an acute heart attack, a remodeling process was initiated in the heart in an attempt to compensate for the damaged areas.

Researchers surmised that the condition of the heart muscle several weeks after the attack may differ considerably from the heart muscle in the acute stage setting. For some patients, delaying the delivery of stem cells by two to three weeks may have been better than initiating the treatment during the acute phase.

All patients underwent baseline assessments that included medical history, physical exam, electrocardiogram, blood draws, echocardiogram (ECG) and magnetic resonance imaging (MRI) tests. Participants were then assigned randomly to receive the stem cells or placebo within the aforementioned two-to-three week timeline.

The morning of stem cell or placebo infusion, a blood draw and bone marrow aspiration procedure of the hip bone are conducted to collect the stem cells. Later the same day, either stem cells or placebo are then infused through a catheter and directly into the damaged area of the heart.

Following the first 24 hours of the infusion, participants wear a small ECG machine, or Holter monitor. Additionally, patients record their body temperature twice a day for 30 days post infusion. Follow up visits at months one, three, six, 12 and 24 where baseline assessment testing are conducted.

The TIME trial adjusts that variable and results will be published in two years.

For more information: www.uhhospitals.org/case/tabid/853/uhcasemedicalcenter.aspx

Related Content About Stem Cell Therapies to Restore Heart Function

FDA Says Adult Stem Cell Research Shows Promise

Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina

3-D Printed Patch Can Help Mend "Broken" Heart

Cardiac Regeneration After MI: Role of the Extracellular Matrix

Resurrecting Dead Heart Tissue

 

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init